ABSTRACT

This invention provides a compound of the formula (I):



(I)

or the pharmaceutically acceptable salts thereof, wherein Y^1, Y^2, Y^3 and Y^4 are independently selected from N, CH, etc.; R^1 is H, C_{1-8} alkyl, etc.; Q^1 is a 5-12 membered monocyclic or bicyclic aromatic ring optionally containing up to 4 heteroatoms selected from O, N and S, etc.; A is a 5-6 membered monocyclic aromatic ring optionally containing up to 3 heteroatoms selected from O, N and S, etc.; B is C_{1-6} alkylene optionally substituted with an oxo group, etc.; W is NH, O, etc.; R^2 is H, C_{1-4} alkyl, etc.; Z is a 5-12 membered monocyclic or bicyclic aromatic ring optionally containing up to 3 heteroatoms selected from O, N and S, etc.; L is halo, C_{1-4} alkyl, etc.; m is 0, 1 or 2; R^3 and R^4 are independently selected from H and C_{1-4} alkyl ; R^5 is H, C_{1-4} alkyl, etc.; Q^2 is a 5-12 membered monocyclic or bicyclic aromatic ring or tricyclic ring optionally containing up to 3 heteroatoms selected from O, N and S, etc. These compounds are useful for the treatment of medical conditions mediated by prostaglamndin such as pain, fever or inflammation, etc. This invention also provides a pharmaceutical composition comprising the above compound.